Tamoxifen has been in the news recently. In March, WebMD reported on a
study which showed that a full five year course of the drug had a better chance
of preventing future cancers than a shorter two year course.

Recently the Pharmaceutical Journal has reported on research published in The
Lancet which gives the encouraging news that women with oestrogen receptor-
positive breast cancers who have used Tamoxifen continue to experience
benefits for a decade after they stop taking it. The study suggests long-term
mortality rates could be cut by as much as a third.